147 related articles for article (PubMed ID: 2834736)
1. Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys.
Murray MG; Kuhn RJ; Arita M; Kawamura N; Nomoto A; Wimmer E
Proc Natl Acad Sci U S A; 1988 May; 85(9):3203-7. PubMed ID: 2834736
[TBL] [Abstract][Full Text] [Related]
2. Construction of a poliovirus type 1/type 2 antigenic hybrid by manipulation of neutralization antigenic site II.
Murdin AD; Wimmer E
J Virol; 1989 Dec; 63(12):5251-7. PubMed ID: 2479772
[TBL] [Abstract][Full Text] [Related]
3. Construction and characterization of a poliovirus/rhinovirus antigenic hybrid.
Altmeyer R; Murdin AD; Harber JJ; Wimmer E
Virology; 1991 Oct; 184(2):636-44. PubMed ID: 1653493
[TBL] [Abstract][Full Text] [Related]
4. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice.
Martin A; Wychowski C; Couderc T; Crainic R; Hogle J; Girard M
EMBO J; 1988 Sep; 7(9):2839-47. PubMed ID: 2460345
[TBL] [Abstract][Full Text] [Related]
5. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
[TBL] [Abstract][Full Text] [Related]
6. Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles.
Delpeyroux F; Van Wezel E; Blondel B; Crainic R
J Virol; 1990 Dec; 64(12):6090-100. PubMed ID: 2173781
[TBL] [Abstract][Full Text] [Related]
7. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
[TBL] [Abstract][Full Text] [Related]
8. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
[TBL] [Abstract][Full Text] [Related]
9. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
[TBL] [Abstract][Full Text] [Related]
10. Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I.
Murray MG; Bradley J; Yang XF; Wimmer E; Moss EG; Racaniello VR
Science; 1988 Jul; 241(4862):213-5. PubMed ID: 2838906
[TBL] [Abstract][Full Text] [Related]
11. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted.
Couderc T; Martin A; Wychowski C; Girard M; Horaud F; Crainic R
J Gen Virol; 1991 Apr; 72 ( Pt 4)():973-7. PubMed ID: 1707949
[TBL] [Abstract][Full Text] [Related]
12. Studies on the immunogenicities of intertypic chimeric polioviruses.
Cai H; Dai C
Chin Med Sci J; 1992 Dec; 7(4):209-12. PubMed ID: 1339158
[TBL] [Abstract][Full Text] [Related]
13. Antigen chimaeras of poliovirus as potential new vaccines.
Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
[TBL] [Abstract][Full Text] [Related]
14. The effect of site and mode of expression of a heterologous antigenic determinant on the properties of poliovirus hybrids.
Murdin AD; Mirzayan C; Kameda A; Wimmer E
Microb Pathog; 1991 Jan; 10(1):27-37. PubMed ID: 1713280
[TBL] [Abstract][Full Text] [Related]
15. Poliovirus antigenic hybrids simultaneously expressing antigenic determinants from all three serotypes.
Murdin AD; Lu HH; Murray MG; Wimmer E
J Gen Virol; 1992 Mar; 73 ( Pt 3)():607-11. PubMed ID: 1372037
[TBL] [Abstract][Full Text] [Related]
16. [Studies of purification, inactivity and immunogenicity of antigenically chimeric poliovirus].
Cai H; Dai C
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Oct; 15(5):349-53. PubMed ID: 8168218
[TBL] [Abstract][Full Text] [Related]
17. Antigenic structure of polioviruses of serotypes 1, 2 and 3.
Minor PD; Ferguson M; Evans DM; Almond JW; Icenogle JP
J Gen Virol; 1986 Jul; 67 ( Pt 7)():1283-91. PubMed ID: 2425046
[TBL] [Abstract][Full Text] [Related]
18. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.
Ferguson M; Evans DM; Magrath DI; Minor PD; Almond JW; Schild GC
Virology; 1985 Jun; 143(2):505-15. PubMed ID: 2414909
[TBL] [Abstract][Full Text] [Related]
19. Identification of an antigenic site in the neutralization of type 3 poliovirus.
Minor PD; Evans DM; Schild GC; Ferguson M; Almond JW
Rev Infect Dis; 1984; 6 Suppl 2():S516-8. PubMed ID: 6330849
[TBL] [Abstract][Full Text] [Related]
20. Characterization of human monoclonal antibodies that neutralize multiple poliovirus serotypes.
Puligedda RD; Kouiavskaia D; Al-Saleem FH; Kattala CD; Nabi U; Yaqoob H; Bhagavathula VS; Sharma R; Chumakov K; Dessain SK
Vaccine; 2017 Oct; 35(41):5455-5462. PubMed ID: 28343771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
